Is Electroconvulsive Therapy (ECT) FDA Approved?

ECT devices are FDA-regulated medical devices, but the answer to whether they are “FDA approved” depends on what you mean by that phrase. In 2018, the FDA reclassified ECT devices from their most restrictive category (Class III) down to Class II for a specific set of psychiatric conditions, effectively clearing the way for their continued use without requiring the rigorous premarket approval process normally demanded of high-risk devices. That reclassification applies only to certain diagnoses and patient groups, though, and the regulatory story behind it spans decades of controversy, public comment, and shifting science.

What the FDA Actually Did in 2018

Medical devices and drugs follow different regulatory paths. When people ask whether something is “FDA approved,” they usually picture the process a new medication goes through: clinical trials, a formal application, and an approval letter. Devices work differently. They are sorted into three classes based on risk, and the level of scrutiny scales accordingly. Class I devices (tongue depressors, bandages) face minimal regulation. Class II devices (powered wheelchairs, some surgical instruments) require manufacturers to meet “special controls” and usually submit a premarket notification. Class III devices (implantable defibrillators, for instance) face the strictest path and typically need full premarket approval with clinical data.

ECT devices had been stuck in a regulatory gray zone for years. They were technically classified as Class III since 1979, but the FDA never actually enforced the requirement that manufacturers submit premarket approval applications. The devices stayed on the market under a kind of regulatory limbo. In 2018, the FDA issued a final order reclassifying ECT devices into Class II, but only for treating catatonia or a severe major depressive episode linked to major depressive disorder or bipolar disorder, in patients aged 13 and older who are treatment-resistant or need a rapid response due to the severity of their condition.¹ For any use outside those specific indications, ECT devices remain Class III and would need full premarket approval, which no manufacturer has obtained.

So calling ECT “FDA approved” is technically imprecise. The devices are FDA-cleared for a defined set of uses under Class II special controls. For other psychiatric conditions where ECT is sometimes used clinically (schizophrenia, for example, or severe mania without a bipolar depression component), the regulatory status is murkier. Clinicians may still prescribe ECT off-label for those conditions, much as physicians prescribe drugs off-label, but the device classification does not formally cover them.

What ECT Is Cleared to Treat

The 2018 reclassification carved out three specific situations where ECT devices can be marketed as Class II: catatonia, severe major depressive episodes within major depressive disorder, and severe major depressive episodes within bipolar disorder. In all three, the patient must be 13 or older and must either have failed to respond to adequate trials of other treatments or face a clinical situation urgent enough to justify a rapid intervention.

In practice, ECT sees its widest use in treatment-resistant depression. A randomized trial comparing ECT to the antidepressant paroxetine in medication-resistant patients found that ECT reduced depression scores by about 59%, compared with 29% for the drug, and roughly seven out of ten ECT patients met the threshold for meaningful clinical response.² Broader reviews consistently describe ECT as effective when medications have failed.³

Catatonia, a condition in which a person becomes unresponsive or rigidly immobile despite being awake, is another area where ECT has strong clinical support. A review of over 500 patients with bipolar disorder found that about 81% of those with catatonic features responded to ECT, the highest response rate among the bipolar subgroups studied. Response rates for bipolar depression and mania were also substantial, at roughly 68% and 75% respectively.⁴

How ECT Works (and What We Still Don’t Fully Understand)

ECT involves passing a controlled electrical current through the brain to deliberately trigger a brief seizure, typically lasting under a minute, while the patient is under general anesthesia and given a muscle relaxant. The treatment is usually administered two to three times a week over a course of several weeks.

The honest answer about how this produces its effects is that nobody has a single, clean explanation. Research points to a constellation of changes rather than one mechanism. ECT alters brain chemistry, gene expression, immune function, and the permeability of the blood-brain barrier. It also reshapes functional connectivity between brain regions.⁵ One well-studied piece of the puzzle involves a growth factor called BDNF, which helps neurons survive and form new connections. A large meta-analysis of both animal and human studies found that ECT consistently increased BDNF levels in the brain, with the strongest effects in a part of the hippocampus important for memory and mood regulation.⁶ But BDNF changes alone don’t explain the full picture, and the field is still working to piece together which of these many effects matter most for lifting depression.

The Memory Question

Memory loss is the side effect people worry about most, and the concern is not unfounded. Shortly after a course of ECT, patients tend to have difficulty recalling events from before the treatment, particularly events that are impersonal (public news, cultural events) rather than personal (family milestones, autobiographical details). Bilateral ECT, in which electrodes are placed on both sides of the head, causes more pronounced memory disruption than right unilateral placement, where both electrodes go on one side. By two months after treatment, most of the amnesia has faded, but some deficits in recalling impersonal events and recent details persist.⁷

This is the area where the technique has evolved most meaningfully. Modern ECT practitioners have tools their predecessors lacked. The width of the electrical pulse matters: ultrabrief pulses (shorter than 0.5 milliseconds) cause substantially less memory trouble than the standard brief pulses used historically. In one study, patients receiving ultrabrief right unilateral ECT rated their memory deficits as significantly less severe than patients in any of three other treatment arms (standard bilateral, standard unilateral, and ultrabrief bilateral). The ultrabrief right unilateral group also showed less retrograde amnesia in both the short and long term.⁸ Review-level evidence confirms that ultrabrief right unilateral ECT represents a meaningful technical advance, offering substantially reduced cognitive side effects compared with older protocols.⁹

There’s a tradeoff, though. Ultrabrief bilateral ECT has weaker evidence for efficacy: in one trial its remission rate was only 35%, versus 73% for ultrabrief unilateral and 65% for standard bilateral.⁸ And patients receiving ultrabrief unilateral ECT may need more sessions to get there, responding at a slower pace than those on standard protocols.⁹ Clinicians also now adjust the amplitude of the current, balancing higher amplitudes (which improve antidepressant outcomes) against lower amplitudes (which spare cognition).¹⁰ In practice, the prescribing clinician tailors electrode placement, pulse width, amplitude, and number of sessions to each patient’s needs, balancing effectiveness against cognitive risk.

Physical Safety During Treatment

Because ECT involves both anesthesia and a deliberately induced seizure, there are cardiovascular effects that the treatment team manages in real time. The electrical stimulus initially slows the heart for several seconds, then the seizure triggers a surge of stress hormones. Blood pressure can temporarily double, and heart rate can rise by about 45%. Cardiac output can increase substantially as well. These changes are brief and, in most patients, managed with medications that block the stress-hormone spike.¹¹

Even in patients with cardiac conditions, ECT is generally considered a low-risk procedure compared to the cumulative side effects of long-term psychiatric medications, though cardiovascular events remain the principal (if rare) source of serious complications.¹² The anesthesiology involved is not trivial. Elderly patients, pregnant individuals, and those with other significant medical conditions require customized anesthetic plans.¹³

The Relapse Problem

One of the less-discussed realities of ECT is that it works fast but doesn’t necessarily last. A meta-analysis found that about half of patients relapsed within 12 months after a successful course of ECT, even when they continued on antidepressant medication afterward. Most of those relapses happened in the first six months. Taking antidepressants after ECT cut the relapse risk roughly in half compared to placebo, but even with medication, the rates remained high.¹⁴

A more recent follow-up study found a similar pattern: of patients who achieved remission, 56% had relapsed by six months.¹⁵ Looking out to two years, the overall relapse rate settled around 50%. Interestingly, patients who had psychotic features alongside their depression were actually less likely to relapse, while those who had been resistant to medications before ECT were far more likely to relapse.¹⁶

This relapse vulnerability is why many clinicians now use maintenance ECT: periodic sessions (often monthly, sometimes more or less frequent) to sustain the initial gains. The meta-analytic data suggests that continuing ECT sessions produces a six-month relapse rate comparable to that of continuation medications alone, around 37%.¹⁴ Neither strategy is a guarantee, but the combination of maintenance ECT plus medication has become common practice for patients at high risk of relapse.

State Laws Add Another Layer of Regulation

Even though the FDA regulates the device itself, individual U.S. states impose their own rules on how, when, and by whom ECT can be administered. The variation is enormous. A systematic review found that six states had no laws pertaining to ECT at all, while states like California, Illinois, Texas, and New York were among the most heavily regulated. The rules differ on who can receive ECT, who can consent to it, who can prescribe or perform it, and what reporting and fee requirements providers must meet.¹⁷

The trend in recent years has been toward more restriction, not less. Nearly all newly enacted state-level ECT laws are restrictive in nature, tightening age limits, consent processes, or practitioner qualifications.¹⁸ This creates a patchwork where your ability to receive ECT depends partly on your zip code. For someone in a rural area of a heavily regulated state, access can be extremely limited. Even in states without restrictive laws, practical barriers often stand in the way. The most commonly reported barriers among ECT providers are lack of physical space, stigma on the part of patients themselves, transportation difficulties, and a shortage of trained practitioners. ECT provider density varies dramatically by region, with some parts of the country having six times as many providers per capita as others.¹⁹

Divergent Patient Experiences

Surveys of people who have undergone ECT produce strikingly divided results. A large survey of over 1,100 ECT recipients and their family members found that most recipients (about 62%) reported that ECT made their overall quality of life worse, and roughly a quarter said it made quality of life “very much worse.”²⁰ That’s a jarring number to set against the clinical trial data showing high response rates. What explains the gap?

Part of the answer is methodological: large online surveys of ECT recipients tend to attract people with strong feelings, and advocacy groups critical of ECT actively promoted participation in this particular survey. Another part is that “response” on a depression scale and “improved quality of life” as the patient defines it are different measurements. A person who saw their depression scores drop but who was left with persistent memory gaps may reasonably say their quality of life worsened. Other research paints a different picture. A study tracking quality of life over two years after ECT for treatment-resistant depression found that about 40 to 50% of individuals experienced meaningful improvement, with those who had the strongest initial antidepressant response reporting the best outcomes over time.²¹

The takeaway is that ECT is not one experience. It varies tremendously depending on the technique used, the severity of the illness being treated, whether the patient responds, how their memory is affected, and how their post-ECT care is managed. Informed consent for ECT needs to be genuinely informed, covering not just the probability of response but the real cognitive risks and the high probability of relapse without continuation therapy.

How ECT Compares to Newer Neuromodulation Treatments

ECT is often described as the “gold standard” for treatment-resistant depression, particularly in older adults, but it is no longer the only brain-stimulation option.²² Transcranial magnetic stimulation (TMS) is also FDA-cleared and uses magnetic pulses rather than electrical current. TMS has far fewer cognitive and physical side effects than ECT, and it doesn’t require anesthesia, but it is less effective for psychotic depression and for the most severe, multiply treatment-resistant cases. Vagus nerve stimulation (VNS), which involves an implanted device that sends electrical signals through a nerve in the neck, has shown effectiveness in chronic treatment-resistant depression but has limited data in older patients.

Several investigational approaches are also in development. Magnetic seizure therapy deliberately induces a seizure with magnetic rather than electrical energy, aiming to match ECT’s efficacy while reducing cognitive side effects. Other techniques in earlier stages of research include transcranial direct current stimulation and deep brain stimulation. None of these has yet matched ECT’s track record in the most severe and medication-resistant presentations, but the field is actively trying to find treatments that work as well as ECT without its cognitive costs.

Special Populations

Pregnant individuals and elderly patients are two groups where ECT occupies an unusual niche. In pregnancy, many psychiatric medications carry risks to the developing fetus, and ECT offers a way to treat severe depression or psychosis without prolonged drug exposure. With appropriate medical monitoring, ECT is considered effective and relatively safe across all trimesters and in the postpartum period.²³

The frail elderly, meanwhile, are often described as particularly good candidates. They frequently tolerate psychiatric medications poorly, experiencing falls from sedation, dangerous drug interactions, or cardiac side effects from long-term use. ECT sidesteps those problems, though the anesthesia itself requires careful management in older patients. The FDA’s 2018 reclassification allows use from age 13 upward, but there is no upper age limit. In practice, many ECT services see a disproportionately older patient population. The regulatory picture outside the United States varies. In Australia, ECT is classified as a restricted treatment in most jurisdictions, with its own legislative frameworks governing consent and oversight.²⁴ India recently classified ECT devices as Class C under its own medical device rules, and a push is underway to standardize device manufacturing there.²⁵ The global picture is one of increasing, though uneven, regulation.